Project description:Colorectal cancer (CRC) is the third most common cancer worldwide and liver metastasis remains the major cause of death in CRC. Extensive genomic analysis provided valuable insight into the pathogenesis and progression of CRC. However, the major proteogenomic characterization of CRC liver metastasis is still unknown. We investigated proteogenomic characterization and performed comprehensive integrative genomic analysis of human colorectal cancer liver metastasis.
Project description:Current clinical therapy of non-small cell lung cancer depends on histo-pathological classification. This approach poorly predicts clinical outcome for individual patients. Proteogenomic characterization analysis holds promise to improve clinical stratification, thus paving the way for individualized therapy. We investigated proteogenomic characterization and performed comprehensive integrative genomic analysis of human large cell lung cancer. Here we analyzed proteomes of 29 paired normal lung tissues and large cell lung cancer, identified significantly deregulated proteins associated with large cell lung cancer.
Project description:Integrative analysis of colorectal cancer (CRC) ATAC-seq and RNA-seq revealed an epigenomic and transcriptomic remodeling during liver metastasis.
Project description:Comparison of genomic alterations of primary colorectal cancers with liver metastases of the same patient Keywords: array CGH, colorectal cancer, colon cancer, liver metastasis
Project description:Comparison of genomic alterations of primary colorectal cancers with liver metastases of the same patient Keywords: array CGH, colorectal cancer, colon cancer, liver metastasis 21 primary colorectal cancers and 21 matched liver metastases hybridized against sex-matched control pools
Project description:The genomic VCF data of the Integrative proteogenomic characterization of early esophageal cancer project ,this dataset contains 90 VCF files.
Project description:We report quantification of proteins in human liver microsomal samples from 15 healthy volunteers and 18 patients with cancer in the liver (mainly, colorectal cancer liver metastasis). These data can be used in physiologically based pharmacokinetic models to predict appropriate drug doses in patients with cancer in their liver, especially colorectal cancer liver metastasis.
